In this study, investigators are trying to see if infusion of "m-CTLs" will prevent or treat
cytomegalovirus (CMV), Epstein Barr Virus (EBV) and adenovirus (AdV) reactivation or
infection after cord blood transplant.
Patients with blood cell cancer, other blood disease or a genetic disease may receive a cord
blood transplant (UCBT) from an unrelated donor. After receiving a cord blood transplant,
they are at risk of infections until a new immune system to fight infections grows from the
cord blood cells. In this study, investigators are trying to give special cells from the cord
blood called T cells. These cells will try to fight viruses that can cause infection.
Investigators will test to see if blood cells from donor that have been grown in a special
way, can prevent patients from getting an infection. EBV, AdV and CMV are viruses that can
cause serious life-threatening infections in patients who have weak immune systems after
transplant.
T lymphocytes can kill viral cells but normally there are not enough of them to kill all the
virus infected cells after transplant. Some researcher have taken T cells from a person's
blood, grown more of them in the laboratory and then given them back to the person during a
viral infection after a bone marrow transplant. Some of these studies have shown a positive
therapeutic effect in patients receiving the CTLs (specially trained T cells) after a viral
infection in the post-transplant period. In this study we are trying to prevent or treat
viral infections by given the CTLs soon after getting the umbilical cord blood transplant.
With this study, investigators want to see if they can use a kind of white blood cell called
T cells to prevent or treat AdV, EBV and CMV infection. Investigators will grow these T cells
from the cord blood before transplant. These cells have been trained to attack
adenovirus/EBV/CMV- infected cells and are called multivirus-specific cytotoxic (killer)
T-cells or "m-CTL." Investigators would plan to give patients one dose of m-CTL any time from
30 to 364 days after your transplant. They have used T cells made in this way from the blood
of donors to prevent infections in patients who are getting a bone marrow or blood stem cell
transplant but this will be the first time investigators make them from cord blood.
Phase:
Phase 1
Details
Lead Sponsor:
Children's National Research Institute Children's Research Institute